Want to see SE:ORX full AI Analyst Report?
ORX Stock Chart & Stats
kr34.55
kr0.22(1.39%)
At close: 4:00 PM EST
kr34.55
kr0.22(1.39%)
Day’s Range― - ―
52-Week Rangekr17.50 - kr43.40
Previous CloseN/A
Volume4.04K
Average Volume (3M)101.19K
Market Cap
kr846.85M
Enterprise Valuekr358.47M
Total Cash (Recent Filing)kr386.20M
Total Debt (Recent Filing)kr7.00M
Price to Earnings (P/E)―
Beta0.34
Next Earnings
Jul 16, 2026EPS Estimate
-1.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.24
Shares Outstanding35,127,056
10 Day Avg. Volume22,969
30 Day Avg. Volume101,192
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.12
Price to Sales (P/S)40.09
P/FCF Ratio6.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-7.26
Revenue Forecast (FY)kr25.60M
Bulls Say, Bears Say
Bulls Say
Cash Generation TurnaroundSustained positive operating and free cash flow (~117M TTM) materially improves the company's ability to fund operations, R&D and commercialization without reliance on external financing. Over 2–6 months this underpins liquidity, reduces refinancing risk and enables strategic investments.
Low Current LeverageA very low debt-to-equity (~0.02 TTM) materially lowers financial risk and interest burden, giving management flexibility to allocate cash to growth, pipeline progression or partnerships. This capital structure strength supports durable operational resilience over the medium term.
Specialty Pharma + Digital Therapeutics FocusA concentrated specialty-pharma franchise (U.S. OUD medication) combined with digital therapeutics and potential licensing/partnering revenue creates diversified, higher-margin product and service avenues. This strategic mix supports sustainable revenue channels and lifecycle expansion over the coming months.
Bears Say
Steep Revenue ContractionA greater-than-50% TTM revenue decline indicates structural demand loss or channel disruption. Reduced scale erodes fixed-cost absorption and commercial leverage; without timely stabilization or new revenue sources, the decline will pressure margins and cash conversion beyond the near term.
Persistently Negative MarginsNegative gross, operating and net margins show core operations fail to cover costs. Even with positive cash flow this indicates reliance on non-recurring items or working-capital timing; durable recovery requires either revenue restoration or structural cost reduction to reach sustained profitability.
Historical Balance Sheet VolatilityPrior episodes of high leverage and negative equity signal past funding stress and potential governance or capital-structure risk. This history raises the chance of repeat dilution or refinancing constraints if cash generation weakens, limiting strategic optionality over the medium term.
Orexo AB News
ORX FAQ
What was Orexo AB’s price range in the past 12 months?
Orexo AB lowest stock price was kr17.50 and its highest was kr43.40 in the past 12 months.
What is Orexo AB’s market cap?
Orexo AB’s market cap is kr846.85M.
When is Orexo AB’s upcoming earnings report date?
Orexo AB’s upcoming earnings report date is Jul 16, 2026 which is in 10 days.
How were Orexo AB’s earnings last quarter?
Orexo AB released its earnings results on Apr 28, 2026. The company reported -kr3 earnings per share for the quarter, missing the consensus estimate of N/A by -kr3.
Is Orexo AB overvalued?
According to Wall Street analysts Orexo AB’s price is currently Overvalued.
Does Orexo AB pay dividends?
Orexo AB does not currently pay dividends.
What is Orexo AB’s EPS estimate?
Orexo AB’s EPS estimate is -1.6.
How many shares outstanding does Orexo AB have?
Orexo AB has 35,127,056 shares outstanding.
What happened to Orexo AB’s price movement after its last earnings report?
Orexo AB reported an EPS of -kr3 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.112%.
Which hedge fund is a major shareholder of Orexo AB?
Currently, no hedge funds are holding shares in SE:ORX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
ORX Company Deck
ORX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicates a materially improved financial position driven by the successful sale of ZUBSOLV U.S., resulting in strong cash proceeds (SEK 814 million net) and a net cash position (SEK 429.2 million), while allowing a strategic refocus on the AmorphOX platform and prioritized R&D milestones (OX640 pivotal trial planned Q4, OX390 in‑vivo starting Q1, IZIPRY filing target Q3/2026). However, near-term challenges remain including weak continued-operations revenue (SEK 3.3 million), negative continued-ops EBITDA (SEK -70 million for Q4), impairments (MODIA SEK 22 million), outstanding DOJ investigation risk, bond covenant remediation/possible redemption, restructuring costs in 2026, and reliance on partnerships and BARDA funding to sustain and accelerate development. Overall, the positives from the transaction, cash position, meeting 2025 metrics, and clear strategic direction outweigh the operational and legal headwinds, positioning Orexo to focus on technology-driven R&D growth but with execution and financing risks to monitor.View all SE:ORX earnings summariesTechnical Analysis
AlzeCure Pharma AB
―
Klaria Pharma Holding AB
―
Nanexa AB
―
Enzymatica AB
―
Enorama Pharma AB
―
Options Prices
Currently, No data available
---